Shenzhen Chipscreen Biosciences Balance Sheet Health
Financial Health criteria checks 1/6
Shenzhen Chipscreen Biosciences has a total shareholder equity of CN¥1.6B and total debt of CN¥1.3B, which brings its debt-to-equity ratio to 78.4%. Its total assets and total liabilities are CN¥3.3B and CN¥1.7B respectively.
Key information
78.4%
Debt to equity ratio
CN¥1.29b
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥481.76m |
| Equity | CN¥1.64b |
| Total liabilities | CN¥1.69b |
| Total assets | CN¥3.34b |
Recent financial health updates
Recent updates
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues
Oct 08
Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues
Aug 21We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt
Jun 04Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%
Apr 24Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)
Apr 05Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up
Mar 06Financial Position Analysis
Short Term Liabilities: 688321's short term assets (CN¥1.1B) exceed its short term liabilities (CN¥380.4M).
Long Term Liabilities: 688321's short term assets (CN¥1.1B) do not cover its long term liabilities (CN¥1.3B).
Debt to Equity History and Analysis
Debt Level: 688321's net debt to equity ratio (49.1%) is considered high.
Reducing Debt: 688321's debt to equity ratio has increased from 6.9% to 78.4% over the past 5 years.
Debt Coverage: 688321's debt is not well covered by operating cash flow (2.3%).
Interest Coverage: Insufficient data to determine if 688321's interest payments on its debt are well covered by EBIT.
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 08:24 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Shenzhen Chipscreen Biosciences Co., Ltd. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhizhong Jing | China Merchants Securities Co. Ltd. |
| Bin Wu | China Merchants Securities Co. Ltd. |
| Yinglan Shu | Haitong International Research Limited |